ZA961516B - Use of quinoxalines in combination with protease inhibitors as medicament for treatis aids and/or hiv infections - Google Patents

Use of quinoxalines in combination with protease inhibitors as medicament for treatis aids and/or hiv infections

Info

Publication number
ZA961516B
ZA961516B ZA961516A ZA961516A ZA961516B ZA 961516 B ZA961516 B ZA 961516B ZA 961516 A ZA961516 A ZA 961516A ZA 961516 A ZA961516 A ZA 961516A ZA 961516 B ZA961516 B ZA 961516B
Authority
ZA
South Africa
Prior art keywords
treatis
quinoxalines
aids
medicament
combination
Prior art date
Application number
ZA961516A
Inventor
Arnold Paessens
Martin Blunck
Guenther Reiss
Joerg-Peter Kleim
Manfred Roesner
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA961516B publication Critical patent/ZA961516B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA961516A 1995-02-27 1996-02-26 Use of quinoxalines in combination with protease inhibitors as medicament for treatis aids and/or hiv infections ZA961516B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19506742A DE19506742A1 (en) 1995-02-27 1995-02-27 Use of quinoxalines in combination with protease inhibitors as medicaments for the treatment of AIDS and / or HIV infections

Publications (1)

Publication Number Publication Date
ZA961516B true ZA961516B (en) 1996-09-03

Family

ID=7755115

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA961516A ZA961516B (en) 1995-02-27 1996-02-26 Use of quinoxalines in combination with protease inhibitors as medicament for treatis aids and/or hiv infections

Country Status (19)

Country Link
EP (1) EP0728481A3 (en)
JP (1) JPH08245392A (en)
KR (1) KR960030951A (en)
CN (1) CN1141196A (en)
AR (1) AR003923A1 (en)
AU (1) AU710158B2 (en)
BR (1) BR9600809A (en)
CA (1) CA2170222A1 (en)
CZ (1) CZ57896A3 (en)
DE (1) DE19506742A1 (en)
FI (1) FI960850A (en)
HR (1) HRP960070A2 (en)
HU (1) HUP9600455A3 (en)
IL (1) IL117247A (en)
NO (1) NO960775L (en)
NZ (1) NZ286058A (en)
PL (1) PL312908A1 (en)
SK (1) SK25196A3 (en)
ZA (1) ZA961516B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270546A1 (en) * 1996-11-08 1998-05-22 Japan Energy Corporation Aids remedy
DE19703131A1 (en) * 1997-01-29 1998-07-30 Bayer Ag Use of quinoxaline in a combination of three with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of AIDS and / or HIV infections
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999045009A1 (en) * 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
GB9911887D0 (en) * 1999-05-21 1999-07-21 Glaxo Group Ltd Methods and medicaments for post exposure prophylaxis of an hiv infection
DE10013318A1 (en) * 2000-03-17 2001-09-20 Merck Patent Gmbh Quinoxaline derivatives are used as photo-stable UV filters in cosmetic or pharmaceutical sunscreens for the hair or skin
CA2506415A1 (en) 2002-11-19 2004-06-03 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
JP2016504990A (en) * 2012-12-20 2016-02-18 バイエル ファーマ アクチエンゲゼルシャフト BET protein inhibitory dihydropyridopyrazinone
DE102017005089A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydroquinoxaline-2 (1H) -one
DE102017005091A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2164639T3 (en) * 1991-04-15 2002-03-01 Aventis Pharma Gmbh QUINOXALINAS, PROCEDURE FOR PREPARATION AND EMPLOYMENT.

Also Published As

Publication number Publication date
AR003923A1 (en) 1998-09-30
IL117247A0 (en) 1996-06-18
NO960775L (en) 1996-08-28
IL117247A (en) 2000-10-31
CZ57896A3 (en) 1996-09-11
HUP9600455A2 (en) 1996-12-30
AU710158B2 (en) 1999-09-16
CA2170222A1 (en) 1996-08-28
AU4561596A (en) 1996-09-05
HRP960070A2 (en) 1997-10-31
HUP9600455A3 (en) 1998-04-28
CN1141196A (en) 1997-01-29
KR960030951A (en) 1996-09-17
FI960850A0 (en) 1996-02-23
FI960850A (en) 1996-08-28
DE19506742A1 (en) 1996-08-29
SK25196A3 (en) 1997-05-07
PL312908A1 (en) 1996-09-02
BR9600809A (en) 1997-12-23
EP0728481A2 (en) 1996-08-28
HU9600455D0 (en) 1996-04-29
EP0728481A3 (en) 1998-07-08
JPH08245392A (en) 1996-09-24
NO960775D0 (en) 1996-02-26
NZ286058A (en) 1998-09-24

Similar Documents

Publication Publication Date Title
PL311635A1 (en) Hiv protease inhibitors useful in treating aids
ZA961516B (en) Use of quinoxalines in combination with protease inhibitors as medicament for treatis aids and/or hiv infections
AU6566094A (en) Heterocyclic derivatives in the treatment of ischaemia and related diseases
ZA98679B (en) Use of quinoxalines in a triple combination with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of aids and/or hiv infections
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
AU5127098A (en) Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
AU3099997A (en) The use of tcet in the prophylaxis and treatment of allergies
FI935780A (en) HIV protease inhibitors useful in the treatment of AIDS
GB9409336D0 (en) Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis
GB9515802D0 (en) Hiv protease inhibitors useful for the treatment of aids
AU4812393A (en) Use of rapamycin in the treatment of aids
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
AU5220800A (en) Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments
GB9802542D0 (en) New use
AU1389897A (en) Use of chemokines for the treatment and prevention of hiv infection
AU2001267177A1 (en) Diagnosis and treatment of herpes infections
AU1392601A (en) Prevention and treatment of biomaterial-associated infections
GB9613488D0 (en) HIV protease inhibitors useful in the treatment of aids
EP0914125A4 (en) Hiv protease inhibitors useful for the treatment of aids
IL143795A0 (en) Use of 3-isoxazolidinones and hydroxylamic acids for the treatment of infections
AU2001260291A1 (en) Combination of cerivastatin with ace inhibitors and the use thereof in medicaments
AU3524700A (en) Prevention and treatment of viral infections
AU2002237251A1 (en) A pharmaceutical composition containing benzopyrano-oxopyrimidotetrahydrothiazine and its use in the treatment of hiv
AU4104996A (en) Pepstatin-derivatives for the treatment and detection of fungal infections
AU2001260457A1 (en) Biological materials and methods for use in the prevention or treatment of infections